Maggie L. Shaw

Lab abnormalities can emerge between visits, and pharmacists may be able to catch uncontrolled hematocrit, adherence issues, or access barriers early.

Drugs that form the backbone of CLL therapy are also used across lymphoma subtypes, explains Adam S. Kittai, MD.

Swarup Kumar, MD, of UConn Health, says iberdomide plus dara-dex fills a niche for relapsed disease in patients who lack access to CAR T or bispecifics.

Based on these results, the investigators are extending their follow-up into adolescence.

Previous research shows that in newly diagnosed AML, CR and composite remission rates were higher for shortened regimens of venetoclax.

Previous research has tied the loosening of permit-to-purchase and concealed carry laws to increased firearm suicide rates.

Cell therapy and targeted agents are transforming blood cancer outcomes, but infrastructure, funding, and workforce gaps are limiting who can access them.

The increasingly complex CLL treatment landscape will require continued real-world study to guide sequencing decisions.

The third-gen PCKS9 inhibitor was approved in December 2025 as adjunctive treatment alongside diet and exercise for adults with hypercholesterolemia.

This meta-analysis encompassed 18 studies published through December 31, 2025.

She frames the IberDd approval as more than the addition of 1 more regimen to a crowded relapsed/refractory myeloma armamentarium.

The cereblon E3 ligase modulator, or CELMoD, also received a breakthrough therapy designation from the FDA.

The disparity in outcomes between pediatric and young adult patients with ALL is multifactorial, explained Emily K. Curran, MD.

The BTK inhibitor also showed fewer severe adverse events and better patient-reported quality of life than chemoimmunotherapy.

Oyepeju Abioye-Akintola, MD, MSc explains how the Protocol & People initiative revealed unreadable consent forms as a fixable barrier to clinical and equitable trial enrollment.

Prior to receiving CAR T-cell therapy, patients undergo lymphodepletion chemotherapy, explained Kerry Rogers, MD, The James.

All from July, these 5 novel therapeutics each claimed a “first” in their category.

The authors suggest their data could reflect phlebotomy’s role as a reactive rather than sustained control measure.

Higher CCI scores, prior infection, and prior prophylactic anti-infective treatment were associated with greater risk of subsequent infection in both cancers.

The goal of transplant is to give rise to new immune cells capable of hunting down and destroying resistant leukemic cells, says Karilyn Larkin, MD.

Doris Hansen, MD, co-led "Bridging the Gaps in Health Equity and Access in Multiple Myeloma" on May 2, 2026, in Tampa, Florida.

Novartis says it can deliver doses to treatment sites with 5 days of order.

The researchers of this study warn a mismatch could deepen care gaps for LGBTQ+ patients in restrictive states.

The new MonumenTAL-6 combination data appear to exceed MajesTEC-9 numbers.

New data suggest acalabrutinib appears to reduce the target that macrophages are supposed to recognize in patients with CLL.

An unanswered question: will an additional 7 minutes translate into fewer postcolonoscopy cancers and lower downstream costs?

Rutgers SPH Dean Perry N. Halkitis, PhD, MS, MPH, shares his HIV survival story and why trusted messengers, not statistics, change health behavior.

Each visit incorporated instruments that included symptom burden, fatigue, anxiety and depression, nutritional risk, and patient activation.

These findings reinforce that matching therapy intensity and type to genetic and treatment-history profile is likely to be the next lever for improving outcomes.

HIV disrupts several steps required for durable antibody production; for example, CD4+ helper T cells are depleted and functionally impaired.